US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
EP1462450B1
(en)
*
|
1993-12-29 |
2007-06-13 |
MERCK SHARP & DOHME LTD. |
Substituted morpholine derivatives and their use as therapeutic agents
|
TW385308B
(en)
*
|
1994-03-04 |
2000-03-21 |
Merck & Co Inc |
Prodrugs of morpholine tachykinin receptor antagonists
|
AU690682B2
(en)
*
|
1994-05-05 |
1998-04-30 |
Merck Sharp & Dohme Limited |
Morpholine derivatives and their use as antagonists of tachikinins
|
GB9505491D0
(en)
*
|
1995-03-18 |
1995-05-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9523244D0
(en)
*
|
1995-11-14 |
1996-01-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6117855A
(en)
*
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
US5750549A
(en)
*
|
1996-10-15 |
1998-05-12 |
Merck & Co., Inc. |
Cycloalkyl tachykinin receptor antagonists
|
CA2273856A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating bipolar disorders
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
JP2001504851A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
性的機能不全の治療のためのnk−1受容体拮抗薬の使用
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
ATE282417T1
(de)
*
|
1996-12-02 |
2004-12-15 |
Merck Sharp & Dohme |
Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
|
AU734860B2
(en)
*
|
1996-12-02 |
2001-06-21 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
US6613765B1
(en)
*
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
AU744261B2
(en)
*
|
1997-04-24 |
2002-02-21 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating eating disorders
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
AU737019B2
(en)
*
|
1997-08-04 |
2001-08-09 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating aggressive behaviour disorders
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
AU738047B2
(en)
*
|
1997-08-04 |
2001-09-06 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating mania
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
GB9813025D0
(en)
*
|
1998-06-16 |
1998-08-12 |
Merck Sharp & Dohme |
Chemical synthesis
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
DK1035115T3
(da)
|
1999-02-24 |
2005-01-24 |
Hoffmann La Roche |
4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
|
CN1134417C
(zh)
|
1999-02-24 |
2004-01-14 |
弗·哈夫曼-拉罗切有限公司 |
3-苯基吡啶衍生物及其作为nk-1受体拮抗剂的应用
|
YU59801A
(sh)
|
1999-02-24 |
2005-07-19 |
F. Hoffmann-La Roche Ag. |
Fenil- i piridinil-derivati
|
US6291465B1
(en)
|
1999-03-09 |
2001-09-18 |
Hoffmann-La Roche Inc. |
Biphenyl derivatives
|
FR2792835B3
(fr)
*
|
1999-04-27 |
2001-05-25 |
Sanofi Sa |
Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
|
USRE39921E1
(en)
|
1999-10-07 |
2007-11-13 |
Smithkline Beecham Corporation |
Chemical compounds
|
GB9923748D0
(en)
|
1999-10-07 |
1999-12-08 |
Glaxo Group Ltd |
Chemical compounds
|
US6552025B1
(en)
*
|
1999-11-24 |
2003-04-22 |
Emory University |
Diimino-piperazine derivatives for use as modulators of cell regulation
|
PT1103545E
(pt)
*
|
1999-11-29 |
2004-03-31 |
Hoffmann La Roche |
2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
|
US6452001B2
(en)
|
2000-05-25 |
2002-09-17 |
Hoffmann-La Roche Inc. |
Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
|
US6482829B2
(en)
|
2000-06-08 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
|
DE60134749D1
(de)
|
2000-07-14 |
2008-08-21 |
Hoffmann La Roche |
N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
|
TWI287003B
(en)
|
2000-07-24 |
2007-09-21 |
Hoffmann La Roche |
4-phenyl-pyridine derivatives
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
GB0025354D0
(en)
*
|
2000-10-17 |
2000-11-29 |
Glaxo Group Ltd |
Chemical compounds
|
YU39503A
(sh)
|
2000-11-22 |
2006-05-25 |
F. Hoffmann-La Roche Ag. |
Derivati pirimidina
|
US6642226B2
(en)
|
2001-02-06 |
2003-11-04 |
Hoffman-La Roche Inc. |
Substituted phenyl-piperidine methanone compounds
|
GB0108594D0
(en)
*
|
2001-04-05 |
2001-05-23 |
Glaxo Group Ltd |
Chemical compounds
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
US20030055026A1
(en)
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
US6849624B2
(en)
|
2001-07-31 |
2005-02-01 |
Hoffmann-La Roche Inc. |
Aromatic and heteroaromatic substituted amides
|
US6638981B2
(en)
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
MY130373A
(en)
*
|
2001-10-29 |
2007-06-29 |
Malesci Sas |
Linear basic compounds having nk-2 antagonist activity and formulations thereof
|
US6903129B2
(en)
*
|
2001-12-14 |
2005-06-07 |
Hoffman-La Roche Inc. |
D-proline prodrugs
|
GB0203022D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Glaxo Group Ltd |
Chemical compounds
|
EP1472222A1
(en)
*
|
2002-02-08 |
2004-11-03 |
Glaxo Group Limited |
Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
|
GB0203020D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Glaxo Group Ltd |
Chemical compounds
|
AR039625A1
(es)
*
|
2002-04-18 |
2005-03-02 |
Merck & Co Inc |
Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona
|
WO2003101459A1
(en)
*
|
2002-05-29 |
2003-12-11 |
The Regents Of The University Of California |
Antagonizing nk1 receptors inhibits consumption of substances of abuse
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
CN100562320C
(zh)
|
2003-01-31 |
2009-11-25 |
弗·哈夫曼-拉罗切有限公司 |
2-(3,5-二-三氟甲基-苯基)-N-[6-(1,1-二氧代-1λ6-硫代吗啉-4-基)-4-(4-氟-2-甲基-苯基)-吡啶-3-基]-N-甲基-异丁酰胺的新晶体变体
|
NZ544244A
(en)
|
2003-07-03 |
2008-10-31 |
Hoffmann La Roche |
Dual NK1/NK3 antagonists for treating schizophrenia
|
TWI359675B
(en)
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
US7288658B2
(en)
|
2003-07-15 |
2007-10-30 |
Hoffmann-La Roche Inc. |
Process for preparation of pyridine derivatives
|
US7932272B2
(en)
*
|
2003-09-30 |
2011-04-26 |
Eisai R&D Management Co., Ltd. |
Antifungal agent containing heterocyclic compound
|
US20070020298A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
|
RU2006127432A
(ru)
|
2003-12-31 |
2008-02-10 |
Сайдекс, Инк. (Us) |
Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид, полученная из единичной дозы суспензии
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
ES2246687B2
(es)
|
2004-02-11 |
2006-11-16 |
Miguel Muñoz Saez |
Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
|
WO2005088655A1
(en)
*
|
2004-03-12 |
2005-09-22 |
The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
A magnetoresistive medium
|
AU2005237523A1
(en)
|
2004-04-23 |
2005-11-10 |
Cydex Pharmaceuticals, Inc. |
DPI formulation containing sulfoalkyl ether cyclodextrin
|
KR101389246B1
(ko)
|
2004-07-15 |
2014-04-24 |
브리스톨-마이어스스퀴브컴파니 |
아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
|
JPWO2006016548A1
(ja)
*
|
2004-08-09 |
2008-05-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ヘテロ環化合物を含有する新規な抗マラリア剤
|
WO2006020573A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Barbeau Donald L |
Noncardiotoxic pharmaceutical compounds
|
US7223737B1
(en)
|
2004-08-13 |
2007-05-29 |
Alcon, Inc. |
Method of treating dry eye disorders using glycosides
|
AR051475A1
(es)
*
|
2004-11-05 |
2007-01-17 |
Merck & Co Inc |
Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
|
CN101128429B
(zh)
|
2005-02-22 |
2012-03-21 |
弗·哈夫曼-拉罗切有限公司 |
Nk1拮抗物
|
US20100047338A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
DE602006005624D1
(de)
|
2005-03-23 |
2009-04-23 |
Hoffmann La Roche |
Metaboliten für nk-i-antagonisten zur emesis
|
WO2006106711A1
(ja)
*
|
2005-03-30 |
2006-10-12 |
Eisai R & D Management Co., Ltd. |
ピリジン誘導体を含有する抗真菌剤
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
KR101594898B1
(ko)
|
2005-07-15 |
2016-02-18 |
알바니 몰레큘라 리써치, 인크. |
아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
|
JP5523706B2
(ja)
|
2005-09-23 |
2014-06-18 |
エフ.ホフマン−ラ ロシュ アーゲー |
新規投薬配合物
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
WO2007039883A2
(en)
*
|
2005-10-05 |
2007-04-12 |
Ranbaxy Laboratories Limited |
Process for preparation of aprepitant
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
TWI385169B
(zh)
*
|
2005-10-31 |
2013-02-11 |
Eisai R&D Man Co Ltd |
經雜環取代之吡啶衍生物及含有彼之抗真菌劑
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
CA2640966A1
(en)
*
|
2006-02-03 |
2007-08-09 |
Glenmark Pharmaceuticals Limited |
Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
JP2009526860A
(ja)
*
|
2006-02-15 |
2009-07-23 |
ティカ レーケメデル アーベー |
安定したコルチコステロイド混合物
|
EP2065377B1
(en)
*
|
2006-09-21 |
2011-11-23 |
Eisai R&D Management Co., Ltd. |
Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
|
EP2946778A1
(en)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
EP2117538A1
(en)
|
2007-01-24 |
2009-11-18 |
Glaxo Group Limited |
Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
ATE475645T1
(de)
|
2007-04-20 |
2010-08-15 |
Hoffmann La Roche |
Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten
|
TW200841879A
(en)
|
2007-04-27 |
2008-11-01 |
Eisai R&D Man Co Ltd |
Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
|
WO2008136279A1
(ja)
*
|
2007-04-27 |
2008-11-13 |
Eisai R & D Management Co., Ltd. |
ヘテロ環置換ピリジン誘導体の塩またはその結晶
|
EP1994930A1
(en)
*
|
2007-05-22 |
2008-11-26 |
Novartis AG |
Triazol compounds for treating biofilm formation
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
JP2010535733A
(ja)
|
2007-08-07 |
2010-11-25 |
エフ.ホフマン−ラ ロシュ アーゲー |
Nk3受容体アンタゴニストとしてのピロリジンアリールエーテル
|
US20090076007A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched aprepitant
|
US20090076008A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched fosaprepitant
|
US8513287B2
(en)
|
2007-12-27 |
2013-08-20 |
Eisai R&D Management Co., Ltd. |
Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
|
WO2009104080A2
(en)
|
2008-02-20 |
2009-08-27 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
EP2247185B1
(en)
|
2008-03-03 |
2014-04-16 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
CA2730681C
(en)
*
|
2008-07-17 |
2017-03-07 |
Glenmark Generics Limited |
Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations
|
US8188119B2
(en)
*
|
2008-10-24 |
2012-05-29 |
Eisai R&D Management Co., Ltd |
Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
|
CN102686600A
(zh)
|
2009-02-05 |
2012-09-19 |
托凯药业股份有限公司 |
甾体cyp17抑制剂/抗雄激素物质的新型药物前体
|
KR20110136813A
(ko)
|
2009-03-17 |
2011-12-21 |
다이이찌 산쿄 가부시키가이샤 |
아미드 유도체
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
EA020553B1
(ru)
|
2009-05-12 |
2014-12-30 |
Олбани Молекьюлар Рисерч, Инк. |
7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
|
JP5739415B2
(ja)
|
2009-05-12 |
2015-06-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
(S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
|
WO2010132437A1
(en)
|
2009-05-12 |
2010-11-18 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
AR077328A1
(es)
|
2009-07-24 |
2011-08-17 |
Novartis Ag |
Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
|
US8188079B2
(en)
*
|
2009-08-19 |
2012-05-29 |
Hoffman-La Roche Inc. |
3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
|
MX2012004377A
(es)
|
2009-10-14 |
2012-06-01 |
Merck Sharp & Dohme |
Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
|
WO2011045817A2
(en)
|
2009-10-15 |
2011-04-21 |
Sandoz Private Limited |
Process for the preparation of fosaprepitant, intermediate and pharmaceutical acceptable salt thereof
|
US20130245253A1
(en)
*
|
2010-03-26 |
2013-09-19 |
Department Of Veterans Affairs |
Conjugated Neuroactive Steroid Compositions And Methods Of Use
|
US8487102B2
(en)
|
2010-04-20 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
SG178311A1
(en)
*
|
2010-07-13 |
2012-03-29 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
US9446029B2
(en)
|
2010-07-27 |
2016-09-20 |
Colorado State University Research Foundation |
Use of NK-1 receptor antagonists in management of visceral pain
|
EP2601293B1
(en)
|
2010-08-02 |
2017-12-06 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
ES2376564B1
(es)
|
2010-08-12 |
2013-01-24 |
Manuel Vicente Salinas Martín |
Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
|
AU2011292261B2
(en)
|
2010-08-17 |
2015-05-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US8524897B2
(en)
|
2011-01-12 |
2013-09-03 |
Novartis Ag |
Crystalline oxazine derivative
|
EP2663561B1
(en)
|
2011-01-13 |
2016-03-16 |
Novartis AG |
Novel heterocyclic derivatives and their use in the treatment of neurological disorders
|
CN102127031B
(zh)
*
|
2011-01-17 |
2012-10-17 |
江苏江神药物化学有限公司 |
一种麻黄碱类化合物季胺盐及其合成方法和应用
|
US9067924B2
(en)
*
|
2011-03-04 |
2015-06-30 |
Hoffmann-La Roche Inc. |
1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
|
FR2973031B1
(fr)
*
|
2011-03-23 |
2013-11-29 |
Univ Strasbourg |
Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
|
EP2688901B1
(en)
*
|
2011-03-25 |
2019-05-08 |
Université Laval |
INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
|
US20140045832A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Insulin-Like Growth Factor-1 Receptor Inhibitors
|
WO2012146692A1
(en)
|
2011-04-29 |
2012-11-01 |
Sandoz Ag |
Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
|
KR20140041590A
(ko)
*
|
2011-06-07 |
2014-04-04 |
에프. 호프만-라 로슈 아게 |
[1,3]옥사진
|
EP2729147B1
(en)
|
2011-07-04 |
2017-09-06 |
IRBM - Science Park S.p.A. |
Nk-1 receptor antagonists for treating corneal neovascularisation
|
CN102977142B
(zh)
*
|
2011-09-02 |
2017-03-29 |
江苏豪森药业集团有限公司 |
福沙匹坦二甲葡胺的制备方法
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
WO2013087964A1
(es)
|
2011-12-13 |
2013-06-20 |
Servicio Andaluz De Salud |
Uso de agentes modificadores del ambiente peritumoral para el tratamiento del cáncer
|
US8338413B1
(en)
|
2012-03-07 |
2012-12-25 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
WO2013168176A2
(en)
*
|
2012-03-30 |
2013-11-14 |
Glenmark Generics Limited |
Process for preparation of fosaprepitant and salt thereof
|
CZ304982B6
(cs)
*
|
2012-04-30 |
2015-03-11 |
Zentiva, K.S. |
Způsob přípravy a čištění nových polymorfů intermediátu fosaprepitantu
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
CN102675369B
(zh)
*
|
2012-05-16 |
2017-07-11 |
北京华众思康医药技术有限公司 |
一种制备[3‑[(2r)‑[(1r)‑1‑[3,5‑二(三氟甲基)苯基]乙氧基]‑3(s)‑(4‑氟苯基)吗啉‑4‑基]甲基]‑5‑氧代‑4,5‑二氢‑[1,2,4]‑三唑‑1‑基]膦酸一苄酯的新方法
|
NZ702467A
(en)
*
|
2012-05-31 |
2016-07-29 |
Repros Therapeutics Inc |
Formulations and methods for vaginal delivery of antiprogestins
|
EP2866797B1
(en)
|
2012-07-06 |
2020-04-29 |
Pharmathen S.A. |
Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof
|
MX2015004041A
(es)
|
2012-09-28 |
2015-07-06 |
Merck Sharp & Dohme |
Compuestos novedosos que son inhibidores de erk.
|
JP2016500365A
(ja)
*
|
2012-10-29 |
2016-01-12 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
ビマトプロストおよびプロストアミドのリン酸エステル
|
US8796305B2
(en)
|
2012-11-05 |
2014-08-05 |
Bayer Pharma Aktiengesellschaft |
Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US9126998B2
(en)
|
2012-11-05 |
2015-09-08 |
Bayer Pharma AG |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US9624214B2
(en)
|
2012-11-05 |
2017-04-18 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US8778964B2
(en)
|
2012-11-05 |
2014-07-15 |
Bayer Pharma Aktiengesellschaft |
Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
|
RU2660349C2
(ru)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Композиции и способы для лечения злокачественной опухоли
|
US8846657B2
(en)
|
2012-12-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
ES2493693B1
(es)
|
2013-02-11 |
2015-07-07 |
Servicio Andaluz De Salud |
Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
|
WO2014134413A2
(en)
*
|
2013-03-01 |
2014-09-04 |
Revlon Consumer Products Corporation |
Cyrrhetinic alkyl esters and protected derivatives thereof
|
ES2699445T3
(es)
|
2013-03-13 |
2019-02-11 |
Sage Therapeutics Inc |
Esteroides neuroactivos y métodos de utilización de los mismos
|
EP2968370A4
(en)
|
2013-03-14 |
2016-09-21 |
Univ Maryland |
AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
|
US20160060288A1
(en)
*
|
2013-04-18 |
2016-03-03 |
Xi'anlibang Pharmaceutical Technology Co., Ltd. |
Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
|
CN105339368B
(zh)
|
2013-06-04 |
2017-08-15 |
拜耳制药股份公司 |
3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
|
JP2016528252A
(ja)
|
2013-08-12 |
2016-09-15 |
トーカイ ファーマシューティカルズ, インコーポレイテッド |
アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CN105899223A
(zh)
|
2013-10-28 |
2016-08-24 |
加利福尼亚大学董事会 |
转移性前列腺癌的治疗
|
CN104650142B
(zh)
*
|
2013-11-25 |
2018-06-22 |
山东新时代药业有限公司 |
一种福沙匹坦二甲葡胺的制备方法
|
CN103694146B
(zh)
*
|
2013-12-04 |
2015-10-28 |
深圳万乐药业有限公司 |
2-(2-氯-1-亚乙基)酰肼甲酸甲酯的制备方法
|
ES2541870B1
(es)
|
2013-12-27 |
2016-05-12 |
Servicio Andaluz De Salud |
Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
|
JP2017502973A
(ja)
*
|
2013-12-30 |
2017-01-26 |
オンコプレフェント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌を予防する方法において使用するためのニューロキニン−1受容体アンタゴニスト
|
JP2017507140A
(ja)
|
2014-02-19 |
2017-03-16 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
3−(ピリミジン−2−イル)イミダゾ[1,2−a]ピリジン
|
JP2017508810A
(ja)
|
2014-03-21 |
2017-03-30 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
シアノ置換イミダゾ[1,2−a]ピリジンカルボキサミドおよびその使用
|
TW201613888A
(en)
|
2014-09-26 |
2016-04-16 |
Helsinn Healthcare Sa |
Crystalline forms of an NK-1 antagonist
|
JP2017536396A
(ja)
|
2014-12-02 |
2017-12-07 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
ヘテロアリール置換イミダゾ[1,2−a]ピリジンおよびその使用
|
PE20180482A1
(es)
|
2015-07-06 |
2018-03-07 |
Sage Therapeutics Inc |
Oxiesteroles y metodos de uso de los mismos
|
US10610532B2
(en)
|
2015-08-03 |
2020-04-07 |
Leiutis Pharmaceuticals Pvt. Ltd. |
Liquid formulations of fosaprepitant
|
US10005803B2
(en)
|
2015-10-06 |
2018-06-26 |
Helsinn Healthcare Sa |
Crystalline forms of fosnetupitant
|
US9913853B2
(en)
|
2015-11-03 |
2018-03-13 |
Cipla Limited |
Stabilized liquid fosaprepitant formulations
|
WO2017093899A1
(en)
|
2015-12-01 |
2017-06-08 |
Piramal Enterprises Limited |
A process for preparation of fosaprepitant dimeglumine and an intermediate thereof
|
CN105837526B
(zh)
*
|
2016-01-22 |
2018-02-27 |
浙江工业大学 |
一种阿瑞吡坦重要合成中间体(2s,3r)‑4‑苄基‑3‑(4‑氟苯基)吗啉‑2‑醇的制备方法
|
LT3436022T
(lt)
|
2016-04-01 |
2022-06-27 |
Sage Therapeutics, Inc. |
Oksisteroliai ir jų panaudojimo būdai
|
US10752653B2
(en)
|
2016-05-06 |
2020-08-25 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
CN107353303B
(zh)
|
2016-05-09 |
2020-09-01 |
上海奥博生物医药技术有限公司 |
一种福沙匹坦磷酸酯中间体的制备方法
|
DK3435980T3
(da)
|
2016-06-06 |
2020-02-24 |
Helsinn Healthcare Sa |
Fysiologisk afbalancerede injicerbare formuleringer af fosnetupitant
|
RS62222B1
(sr)
|
2016-07-07 |
2021-09-30 |
Sage Therapeutics Inc |
24-hidroksisteroli supstituisani na poziciji 11 za upotrebu u lečenju stanja povezanih sa nmda
|
MA46351A
(fr)
|
2016-09-30 |
2021-06-02 |
Sage Therapeutics Inc |
Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
|
EP3529256B1
(en)
|
2016-10-18 |
2023-08-09 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
ES2952106T3
(es)
|
2016-10-18 |
2023-10-27 |
Sage Therapeutics Inc |
Oxisteroles y procedimientos de utilización de los mismos
|
EP3609495A4
(en)
|
2017-04-10 |
2020-12-02 |
Chase Therapeutics Corporation |
NK1 ANTAGONIST COMBINATION AND METHOD OF TREATMENT OF SYNUCLEINOPATHIA
|
JP7158425B2
(ja)
|
2017-06-30 |
2022-10-21 |
チェイス セラピューティクス コーポレイション |
Nk-1アンタゴニスト組成物およびうつ病の処置における使用法
|
EP3672964A4
(en)
|
2017-08-21 |
2021-05-26 |
Leiutis Pharmaceuticals Pvt. Ltd. |
NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
|
CN109694390A
(zh)
*
|
2017-10-24 |
2019-04-30 |
齐鲁制药有限公司 |
一种福沙匹坦氮氧化物
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
JP2021514976A
(ja)
|
2018-02-26 |
2021-06-17 |
オスペダーレ・サン・ラッファエーレ・エッセエッレエッレ |
眼痛の治療における使用のためのnk−1拮抗薬
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP4117673A1
(en)
|
2020-03-11 |
2023-01-18 |
Ospedale San Raffaele S.r.l. |
Treatment of stem cell deficiency
|
IL296635A
(en)
|
2020-04-03 |
2022-11-01 |
Nerre Therapeutics Ltd |
An nk-1 receptor antagonist for the treatment of a disease selected from sepsis, septic shock, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome (MODS)
|
KR20230018485A
(ko)
|
2020-06-02 |
2023-02-07 |
네르 쎄라퓨틱스 리미티드 |
폐에 대한 기계적 손상에 의해 촉진된 폐 섬유증 상태의 치료에 사용하기 위한 뉴로키닌 (nk)-1 수용체 길항제
|
EP4248977A1
(en)
|
2020-11-19 |
2023-09-27 |
Nippon Kayaku Kabushiki Kaisha |
Composition containing water-soluble drug capable of inducing vascular disorder, solution for use in preparation of administration solution containing water-soluble drug capable of inducing vascular disorder, kit, vascular disorder preventing agent, and solution containing nonionic surfactant
|
EP4052696A1
(en)
|
2021-03-04 |
2022-09-07 |
Extrovis AG |
Stable ready-to-use parenteral compositions of fosaprepitant
|
CN113582982B
(zh)
*
|
2021-06-15 |
2023-06-16 |
山东罗欣药业集团股份有限公司 |
一种nk1受体拮抗剂的制备方法
|